FDA
-
-
-
-
-
-
-
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
-
-
-
-
-
-
-
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
-
-
-
-
-
-
-
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
-
-
-
-
-
-
-
Regeneron (REGN, Sanofi (SNY): Dupixent Approved as the First-ever Biologic Medicine in Japan for Patients with COPD
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
-
-
-
-
-
-
-
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
-
326,046 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

